• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
    • Cardiovascular
    • Orthopedics
  • Wall Street Beat
    • Funding Roundup
    • Mergers & Acquisitions
  • Podcasts & Webinars
    • Podcasts
    • Webinars
  • Resources
    • About MassDevice
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech 100 Index
    • Videos
    • Whitepapers
  • DeviceTalks Tuesdays
  • Coronavirus: Live updates
Home » Clearances roundup: Tomophase OCTIS wins 510(k) for tomography system

Clearances roundup: Tomophase OCTIS wins 510(k) for tomography system

December 12, 2010 By MassDevice staff

Clearances roundup

Here’s a roundup of companies announcing clearances and approvals from the Food & Drug Administration and foreign regulatory agencies:

  • Tomophase OCTIS wins 510(k) for tomography system
    Tomophase Corp., developer of the non-invasive Optical Coherence Tomography Imaging System (OCTIS) and other devices, announced that it has received FDA 510(k) clearance to market OCTIS. OCTIS is comprised of a single-use disposable optical catheter and imaging console. Initially OCTIS will be deployed for tissue imaging of airways and lungs, followed by diagnostic and therapeutic applications.
    Read more
  • CE Mark announced for ArthroCare’s WoundWand debridement device
    ArthroCare Corp. (NSDQ:ARTC), a minimally invasive surgical products developer, announced Dec. 9 that its WoundWand debridement device received CE (Conformité Européenne) Mark approval and is available for distribution in Europe. Using ArthroCare’s patented Coblation technology, the WoundWand enables necrotic tissue to be removed from a wound in a precise and controlled manner. The WoundWand is intended for wound debridement in acute and chronic wounds and wound cleansing by removal of necrotic tissue.
    Read more
  • Neoprobe granted Pre-IND meeting with FDA to review RIGS technology
    Neoprobe Corp. (OTC:NEOP), a developer of oncology surgical and diagnostic products, announced Dec. 9 that it has requested and been granted a Type B pre-IND meeting with the Food & Drug Administration regarding its RIGS technology Biologic License Application (BLA). The pre-IND meeting request is another step in Neoprobe’s efforts to develop and commercialize the RIGS technology designed to enhance the surgical treatment of patients with solid tumor cancers.
    Read more
  • Hutchinson Technology wins CE Mark approval for InSpectra StO2 Spot Check
    Hutchinson Technology Inc. (NSDQ:HTCH) announced CE Mark and the market launch of the InSpectra StO2 Spot Check for use as a noninvasive tool to rapidly assess the tissue oxygenation of patients in circulatory distress. The company also has filed for marketing clearance of the product in the United States under the Food & Drug Administration’s 510(k) process.
    Read more
  • SANUWAVE Health submits to FDA first module of PMA application for dermaPACE for the treatment of diabetic foot ulcers
    SANUWAVE Health Inc. (OTC:SNWV), an emerging medical technology company focused on regenerative medicine, reported its submission to the Food & Drug Administration of the first of three modules of the Premarket Approval application for the Company’s dermaPACE device for the treatment of diabetic foot ulcers.
    Read more
  • Ellipse Technologies announces CE Mark approval of PRECICETM remote-control leg limb lengthening device
    Ellipse Technologies Inc. announced that it has received CE Mark approval for the company’s PRECICETM limb lengthening device. Limb Lengthening procedures are used to treat a number of medical conditions, including shortened legs due to congenital abnormalities, major fractures of one of the legs and shortened leg bones due to other medical diseases, such as cancer.
    Read more
  • Prodesse ProAdeno+ assay cleared by FDA
    Gen-Probe Inc. (NSDQ:GPRO) announced that the Food & Drug Administration granted 510(k) clearance for the Prodesse ProAdeno+ assay, a multiplex real-time polymerase chain reaction in vitro diagnostic test for the qualitative detection of human adenovirus.
    Read more
  • Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca and Stretta systems
    Mederi Therapeutics Inc. announced that it has received a CE Mark authorizing the European distribution and use of Mederi’s second generation of the Stretta and Secca Systems. The Stretta System is for treatment of gastric reflux disease, commonly known as GERD, and the Secca System is for treatment of bowel control disorder, or BCD. These latest systems include a streamlined user interface, improvements in ease of use, and are smaller, lighter, and more portable.
    Read more
  • Valeritas Receives FDA 510(k) clearance for the V-Go disposable insulin delivery device
    Valeritas Inc., a medical technology company committed to the development and commercialization of innovative drug delivery solutions, announced Dec. 8 that the Food & Drug Administration cleared the company’s V-Go Disposable Insulin Delivery Device for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin. V-Go devices will be available in a preset basal rate to deliver 20, 30 or 40 Units of insulin in one 24-hour period (0.83 U/hr, 1.25U/hr or 1.67U/hr respectively) and on-demand bolus dosing in 2 Unit increments (up to 36 Units per one 24-hour time period).
    Read more
  • Orthovita receives FDA clearance for Vitoss Bioactive Foam-2X bone graft substitute
    Orthovita Inc. (NSDQ:VITA), an orthobiologics and biosurgery company, announced that it received 510(k) clearance from the Food & Drug Administration to market Vitoss Bioactive Foam-2X Bone Graft Substitute for use as a non-structural bone void filler for use in the spine, pelvis and extremities. Orthovita expects to launch the newest addition to its bone graft substitute product line by late February or early March of 2011.
    Read more
  • Cytomedix receives ISO 13485 and Canadian Medical Device certifications
    Cytomedix Inc. (NYSE:GTF) announced Dec. 7 that it has received certification for the ISO 13485 Quality Management Standard for Medical Devices as well as Canadian Medical Device Certification for its Gaithersburg facility. The announcement certifies Cytomedix as a provider of devices for the medical industry and allows the company to operate commercially in Europe and in Canada.
    Read more

Filed Under: Business/Financial News, News Well Tagged With: Gift Bans

In case you missed it

  • How Stryker includes users for product design in the digital age
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
  • FDA approves Medtronic’s Onyx Frontier drug-eluting coronary stent
  • Medtronic completes Intersect ENT acquisition
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
  • Medtronic must sell Intersect ENT subsidiary to satisfy FTC concerns
  • Abbott partners with Women as One to help more underrepresented clinicians lead trials
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
  • Abbott announces availability of Xience Skypoint drug-eluting stent in extended sizes
  • GE Healthcare to invest $50M in Pulsenmore to enter homecare segment
  • BD launches automated infectious disease diagnostic platform in the U.S.
  • DarioHealth rises on Street-beating Q1
  • Here’s what’s next for Insulet after the launch of Omnipod 5, CEO change
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
  • Moderna’s new CFO leaves after former employer discloses investigation
  • How technology is changing the operating room

RSS From Medical Design & Outsourcing

  • How Stryker includes users for product design in the digital age
    Medical device developers and manufacturers like Stryker (NYSE:SYK) are changing how they approach design as digital technology becomes more crucial. Four Stryker executives shared how the Kalamazoo, Michigan–based orthopedic device giant is thinking differently about medical product development and how health care providers and patients will ultimately use them. The DeviceTalks Boston panel of Stryker… […]
  • DermaSensor wins MedTech Innovator Mid-Stage Companies Pitch Event
    DermaSensor Inc. — the creator of a handheld, point-and-click device to quickly assess skin lesions for cancer risk — is the winner of the MedTech Innovator Mid-Stage Companies Pitch Event.  The Miami-based mid-stage company beat out 1,000 applicants, more than 20 of which competed on-site May 10–11, 2022 at DeviceTalks Boston. DermaSensor walked away with… […]
  • Steris rises on Street-beating Q4, sets fiscal 2023 guidance
    Steris (NYSE:STE) shares ticked up today on fourth-quarter financial results that came in just ahead of the consensus forecast. The infection prevention technology company — headquartered in Dublin, Ireland, and run operationally out of Mentor, Ohio — posted profits of $52.3 million, or 52¢ per share, on sales of $1.2 billion for the three months… […]
  • Lucira Health asks FDA for EUA on molecular at-home COVID/flu test
    Lucira Health (Nasdaq: LHDX) today said it has asked the FDA for an emergency use authorization (EUA) for its combination COVID-19 and flu test. Emeryville, California–based Lucira said the at-home test would be available with a prescription to test for SARS-CoV-2, Influenza A and Influenza B. The Nucleic Acid Amplification Test (NAAT) platform has a… […]
  • Device commercialization platform AcuityMD raises $31M Series A to fund R&D engineer hiring
    AcuityMD said today it has raised $31 million in Series A funding for its medical device commercialization platform. “With our new funding, we plan to double down on R&D by growing our engineering team from 15 to over 40 over the next year,” AcuityMD co-founder and CEO Michael Monovoukas said in a blog post. “We’ll… […]
  • Rockley Photonics announces $81.5M private placement
    Rockley Photonics (NYSE:RKLY) announced today that it entered into agreements for an $81.5 million private placement. Participating investors agreed to purchase $81.5 million in convertible senior secured notes (due 2026) and warrants to purchase 26.5 million Rockley ordinary shares at an exercise price of $5 per share, subject to certain anti-dilution adjustments. Warrants purchased in… […]
  • Stryker leaders talk medtech trends at DeviceTalks Boston: ‘If you’re slow, you’re going to lose’
    The first day of DeviceTalks Boston closed with a panel of Stryker (NYSE:SYK) executives discussing new tools, technologies and strategies in medtech. Digital VP Tracy Robertson, Digital, Robotics, and Enabling Technologies President Robert Cohen and Surgical Technologies VP of Digital Innovation Siddarth Satish offered their thoughts on industry trends in healthcare and at the Kalamazoo,… […]
  • Medtronic’s VC leader discusses risk, returns, strategy and an ‘ugly truth’
    A panel of medtech investors convened today for DeviceTalks Boston included David Neustaedter, VP of venture capital at Medtronic (NYSE: MDT). He’s spent 14 years in the role, including as director of venture capital at Covidien before Medtronic acquired the company. (Read more in his DeviceTalks speaker bio.) Medtronic has more than $500 million in… […]
  • Here’s where Harvard’s engineering dean sees medtech research going
    Surgical robotics, artificial intelligence, and combatting climate change are but some of the priorities that have Harvard’s engineering school dean excited. Speaking today at DeviceTalks Boston, Frank J. Doyle III described the Harvard John A. Paulson School of Engineering and Applied Sciences as a “well-kept secret” historically. But Harvard engineering is staking out a strong position when it… […]
  • gBETA Medtech accelerator picks its next startups
    The gBETA Medtech virtual accelerator today named the five startups that will participate in the spring program leading up to the June 21 showcase day. The five startups for the spring 2022 cohort are: Mother of Fact: This mobile app for moms with babies offers nutrition tracking, preventative monitoring and daily coaching from licensed dietitians… […]
  • FDA warns of potential toxic risk from Fresenius hemodialysis machines
    The FDA is evaluating the risk of exposure to toxic chemicals from silicone tubing used in Fresenius Medical Care (NYSE: FMS) hemodialysis machines. The investigation concerns three models of Fresenius hemodialysis machines: the 2008T, 2008K2, and 2008K. The chemicals — non-dioxin-like (NDL) polychlorinated biphenyl acids (PCBAs) and NDL polychlorinated biphenyls (PCBs) — are in the… […]

Leave a Reply

You must be logged in to post a comment.

Primary Sidebar

DeviceTalks Weekly

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Medtech news in a minute?
We Deliver!

MassDevice Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World

Device Talks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our Device Talks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us
Add us on Facebook Follow us on Twitter Connect with us on LinkedIn Follow us on YouTube

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS